These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15706463)

  • 21. Functional characterization of the nonpeptide neurokinin3 (NK3) receptor antagonist, SR142801 on the human NK3 receptor expressed in Chinese hamster ovary cells.
    Oury-Donat F; Carayon P; Thurneyssen O; Pailhon V; Emonds-Alt X; Soubrié P; Le Fur G
    J Pharmacol Exp Ther; 1995 Jul; 274(1):148-54. PubMed ID: 7616392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
    Demiralay C; Jahn H; Kellner M; Yassouridis A; Wiedemann K
    World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.
    Kellner M; Wiedemann K; Yassouridis A; Levengood R; Guo LS; Holsboer F; Yehuda R
    Biol Psychiatry; 2000 Jan; 47(2):107-11. PubMed ID: 10664826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers.
    Bradwejn J; LeGrand JM; Koszycki D; Bates JH; Bourin M
    Am J Psychiatry; 1998 Feb; 155(2):280-2. PubMed ID: 9464212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males.
    Goettel M; Fuertig R; Mack SR; Just S; Sharma V; Wunder A; den Boer J
    CNS Drugs; 2023 Dec; 37(12):1099-1109. PubMed ID: 38019356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.
    Bradwejn J; Koszycki D; Meterissian G
    Can J Psychiatry; 1990 Feb; 35(1):83-5. PubMed ID: 2180549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
    Bradwejn J; Koszycki D; Shriqui C
    Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
    Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
    Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings.
    Bradwejn J; Koszycki D; Payeur R; Bourin M; Borthwick H
    Am J Psychiatry; 1992 Jul; 149(7):962-4. PubMed ID: 1609879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of aging on cholecystokinin-induced panic.
    Flint AJ; Koszycki D; Vaccarino FJ; Cadieux A; Boulenger JP; Bradwejn J
    Am J Psychiatry; 1998 Feb; 155(2):283-5. PubMed ID: 9464213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.
    Ströhle A; Kellner M; Holsboer F; Wiedemann K
    Am J Psychiatry; 2001 Sep; 158(9):1514-6. PubMed ID: 11532742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.
    Tõru I; Shlik J; Maron E; Vasar V; Nutt DJ
    Psychopharmacology (Berl); 2006 May; 186(1):107-12. PubMed ID: 16541242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys.
    De Souza Silva MA; Mello EL; Müller CP; Jocham G; Maior RS; Huston JP; Tomaz C; Barros M
    Eur J Pharmacol; 2006 May; 536(3):269-78. PubMed ID: 16603151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder.
    van Megen HJ; Westenberg HG; Den Boer JA; Kahn RS
    Eur Neuropsychopharmacol; 1996 Aug; 6(3):187-94. PubMed ID: 8880078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers.
    Tõru I; Aluoja A; Võhma U; Raag M; Vasar V; Maron E; Shlik J
    Psychiatry Res; 2010 Jul; 178(2):342-7. PubMed ID: 20471107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4).
    Zwanzger P; Eser D; Völkel N; Baghai TC; Möller HJ; Rupprecht R; Padberg F
    Int J Neuropsychopharmacol; 2007 Apr; 10(2):285-9. PubMed ID: 16817979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.
    Katzman MA; Koszycki D; Bradwejn J
    Depress Anxiety; 2004; 20(2):51-8. PubMed ID: 15390214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls.
    Koszycki D; Torres S; Swain JE; Bradwejn J
    Psychosom Med; 2005; 67(4):590-5. PubMed ID: 16046372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholecystokinin and panic disorder: past and future clinical research strategies.
    Bradwejn J; Koszycki D
    Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aging and panicogenic response to cholecystokinin tetrapeptide: an examination of the cholecystokinin system.
    Flint A; Bradwejn J; Vaccarino F; Gutkowska J; Palmour R; Koszycki D
    Neuropsychopharmacology; 2002 Oct; 27(4):663-71. PubMed ID: 12377403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.